Related Experiment Video

Updated: Jan 14, 2026

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

10.8K

Diagnostic and Prognostic Potential of Tetranectin in Heart Failure and Cardiovascular Disease: A Systematic Review

Paula Alexandra Vulciu1, Luminita Pilat1, Maria-Daniela Mot2

  • 1Department of Biochemistry, "Vasile Goldis" Western University, B-dul Revolutiei Nr. 96, 310025 Arad, Romania.

Medical Sciences (Basel, Switzerland)
|October 24, 2025
PubMed

Insights

Tetranectin shows promise as a biomarker for cardiovascular diseases like heart failure and coronary artery disease. Lower levels indicate higher risk, while higher levels suggest better outcomes, potentially improving risk stratification.

Area of Science:

  • Biochemistry
  • Cardiology
  • Biomarker Discovery

Background:

  • Tetranectin (CLEC3B) is a plasminogen-binding protein implicated in fibrinolysis and tissue remodeling.
  • Its role as a diagnostic and prognostic biomarker in cardiovascular disease (CVD) is under investigation.
  • This review synthesizes evidence on tetranectin's clinical utility in heart failure (HF) and coronary artery disease (CAD).

Purpose of the Study:

  • To systematically evaluate and synthesize published clinical evidence on the diagnostic and prognostic value of tetranectin in cardiovascular diseases.
  • Assess tetranectin's utility in heart failure, coronary artery disease, myocardial infarction, and related cardiometabolic conditions.

Main Methods:

  • Systematic literature search of PubMed, Google Scholar, and Scopus (January 2010-June 2025).
  • Inclusion of original human observational studies in adults; exclusion of experimental, in vitro, and pediatric studies.
  • Independent data extraction and consensus-based resolution of discrepancies by two reviewers.

Main Results:

  • Twelve studies met inclusion criteria.
  • Lower tetranectin levels were observed in patients with CAD, MI, and advanced HF.
  • Higher tetranectin levels correlated with reduced risk of HF onset, cardiovascular death, and hospitalization.
  • Combination with NT-proBNP enhanced diagnostic accuracy in two studies.
  • Mechanistic insights linked tetranectin to fibrosis-related gene pathways.

Conclusions:

  • Tetranectin demonstrates significant potential as a diagnostic and prognostic biomarker for CVD, especially HF and CAD.
  • Its biological relevance is supported by roles in fibrotic remodeling and vascular homeostasis.
  • Combining tetranectin with existing biomarkers may refine cardiovascular risk stratification and personalize treatment strategies.
  • Further large-scale, longitudinal studies are necessary to confirm clinical utility across diverse patient populations.
Abstract

Keywords:
CLEC3BNT-proBNPcardiac biomarkercoronary artery diseasefibrosisheart failureprognosistetranectin

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
535
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
317
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
707
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
209
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
464
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
413